Top Stories
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
The companies will combine clinical trial findings with real-world patient data to investigate treatment outcomes, including measures of health beyond weight loss.
The MIT spinout says six of the world's 20 largest drugmakers have partnered with it to access its biomolecular AI models.
The decision follows scrutiny over her positions on vaccines, mifepristone and other health policy issues.
The Mass General Brigham spinout is building AI models that can draw insights from patients' medical histories.
Conference News
Philips introduces Advanced Image Insights for advanced visualization and AI orchestrationCloud-based solution brings advanced clinical tools and AI insights into radiology workflows, connecting image...
CHICAGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), will present recent evidence on th...
Virta presented research at ObesityWeek 2026 showing their AI-powered, individualized nutrition care clears brain fog, eases depression and anxiety, and reduces physical painDENVER--(BUSINESS WIRE)-- ...
Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisionsCHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM) today announced that 16 a...
DUSSELDORF, Germany--(BUSINESS WIRE)-- Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking p...



